Rosetta Biosoftware Licenses Rosetta Resolver® Gene Expression Data Analysis System to the University of California, Los Angeles

SEATTLE, Wash. and LOS ANGELES, Calif., February 26, 2007 – Rosetta Biosoftware announced today that the University of California, Los Angeles (UCLA) licensed the Rosetta Resolver® system to support research at UCLA's Jonsson Comprehensive Cancer Center (JCCC).

UCLA's JCCC is designated by the National Cancer Institute as a comprehensive treatment facility with a membership of 230 physicians and scientists. They have established an international reputation for developing new cancer therapies, including the breast cancer drug, Herceptin. The Resolver system will be used as a gene expression analysis framework to investigate potential new therapies.

"The Resolver system will be an important asset to our research because of its data management and analysis capabilities for gene expression profiling," said Dr. Richard Finn, M.D., Member of the JCCC Signal Transduction and Therapeutics Program Area.

“We are pleased and honored to provide the Resolver system to the prestigious Jonsson Comprehensive Cancer Center," said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware." JCCC’s use of the Resolver system is in line with Rosetta Biosoftware’s mission to develop software solutions to empower research that improves the quality of human life.”

About UCLA's Jonsson Comprehensive Cancer Center

UCLA's Jonsson Comprehensive Cancer Center comprises more than 240 researchers and clinicians engaged in disease research, prevention, detection, control, treatment and education. One of the nation's largest comprehensive cancer centers, the Jonsson center is dedicated to promoting research and translating basic science into leading-edge clinical studies. In July 2006, the Jonsson Cancer Center was named the best cancer center in California by U.S. News & World Report, a ranking it has held for seven consecutive years.

About the Rosetta Resolver System

The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats and applies Rosetta Biosoftware’s proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.

Life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline and Merck & Co., Inc., as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com.

About Rosetta Biosoftware

Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its comprehensive software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE: MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com.

Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Neither Rosetta Inpharmatics nor Merck & Co., Inc. undertakes any obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect the business of Merck & Co., Inc. including, among others, the extent to which Rosetta Inpharmatics' technology platform can be used in drug discovery programs, uncertainty of market acceptance of Rosetta Inpharmatics' technologies, ability to compete against existing technologies, and those mentioned in the cautionary statements in Item 1 of Merck’s Form 10-K for the year ended Dec. 31, 2005, and in its periodic reports on Form 10-Q and Form 8-K (if any) which are incorporated by reference.

Rosetta Resolver and Elucidator are U.S. registered trademarks of Rosetta Inpharmatics LLC.

Editorial Contact:
For Rosetta Biosoftware:
Lisa Owen
+1.206.926.1236

For UCLA's Jonsson Comprehensive Cancer Center:
Kim Irwin
+1.310.206.2805